Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vectus Biosystems Limited (AU:VBS)
ASX:VBS
RESEARCH TOOLSreports
Holding AU:VBS?
Track your performance easily
VBS Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.08 - AU$0.36
Previous CloseAU$0.08
Volume58.06K
Average Volume (3M)36.22K
Market Cap
AU$4.10M
Enterprise ValueAU$8.83M
Total Cash (Recent Filing)AU$1.28M
Total Debt (Recent Filing)AU$6.02M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Feb 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume36,223
Standard Deviation0.19
R-Squared0.07
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)215198.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vectus Biosystems Limited News
PremiumCompany Announcements
Vectus Biosystems Gains Strong Shareholder Support
PremiumCompany Announcements
Vectus Biosystems Advances Drug Trials and Commercialization
PremiumCompany Announcements
Vectus Biosystems Advances Drug Portfolio and Seeks Partnerships
PremiumCompany Announcements
Vectus Biosystems Announces Virtual AGM for 2024
PremiumCompany Announcements
Vectus Biosystems Announces New Share Issuance
PremiumCompany Announcements
Vectus Biosystems Announces Options Lapse
PremiumCompany Announcements
Vectus Biosystems Issues New Employee Incentive OptionsPremiumCompany Announcements
Vectus Biosystems Issues New Employee Incentive OptionsOptions Prices
Currently, No data available
---
Ownership Overview
6.19%
Insiders
― Other Institutional Investors
93.81% Public Companies and
Individual Investors
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.08 and its highest was AU$0.36 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Currently, no data Available
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Feb 21, 2025 which is in 61 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Aug 30, 2024. The company reported -AU$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.022.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 53,253,310 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
---
Vectus Biosystems Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VBS Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.55%
12-Months-Change
Fundamentals
Return on Equity
-93.34%
Trailing 12-Months
Asset Growth
-56.25%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.
---
Technical Analysis
Race Oncology Ltd.
―
Noxopharm Ltd.
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
---